Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference
Panel Date and Time:
Title: Are We Past the Checkpoint?
In addition to the panel, members of Portage’s management team will be in attendance to explore potential collaborations and partnerships with other industry leaders.
For more information on the panel and to register, visit the website.
About
Portage is a clinical-stage immuno-oncology company advancing multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. Lead programs in the Portage portfolio include first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. These programs are being advanced using innovative trial designs and translational data to identify the patient populations most likely to benefit from treatment. The Company’s unique business model leverages a strong network of academic experts and large pharma partners to rapidly and efficiently advance multiple products. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
chuck@lifesciadvisors.com
Media Relations
rmina@lifescicomms.com

Source: Portage Biotech, Inc.